Work

LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.08.037

Authors: R. Dummer, D. Gyorki, J. Hyngstrom, A. Berger, R. Conry, L. Demidov, L. Ning, T. Lawrence, M. Faries, M. Ross

Institutions: University Hospital Zurich, Olivia Newton-John Cancer Wellness & Research Centre, University of Utah, Huntsman Cancer Institute, Rutgers Cancer Institute, University of Alabama at Birmingham, UAB Medicine, Russian Cancer Research Center NN Blokhin, Amgen (United States), Angeles Clinic and Research Institute, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Les Laboratories Pierre Fabre, Eisai, European Society for Medical Oncology, Ipsen

OpenAlex ID: W4297986218

FWCI: 0.311

Cites:

Cited by: 4

Related to: 10